Nuvation Bio Inc.: financial statements

NUVBNYSEHealthcare · Pharmaceutical Preparations

Price

$3.90

November 17, 2026Market cap $1.3B

What Ploutos Investor adds for Nuvation Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line202320242025Average a year
Revenue $0$7.9M$63M
Cost of revenue $0$7.1M–
Gross profit $0$795.0K–
Operating income -$100M-$593M-$213M
Net income -$76M-$568M-$205M
Earnings per share -$0.35-$2.11-$0.60
Earnings per share, basic -$0.35-$2.11-$0.60
Margins
Gross margin –10.1%–
Operating margin –-7,527.3%-338.7%
Net margin –-7,213.8%-325.3%

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2024: License $2.1M, Product –, Research And Development Service Revenue $5.8M
  • 2025: License $38M, Product $25M, Research And Development Service Revenue –
Product20242025Share 2025
License$2.1M$38M61%
Product–$25M39%

From the XBRL of 8 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$10M Due within 2 years$4.4M Leases0.0% Effective tax rate

When the debt falls due

Dec 31, 2025

Due within 2 years

$10M

Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing

  • 2026: $5.1M
  • 2027: $5.1M

Leases

Dec 31, 2025

Operating leases

$4.4M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

20.4%

Effective rate

0.0%

-20.4 pts

The company paid 0.0% in tax on its profit, 20.4 points below the statutory rate it starts from (20.4%). Below, the reasons it gives.

Statutory rate

20.4%

Change in valuation allowance

-21.1 pts

Difference the filing does not itemize

+0.7 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

The full analysis

What do Nuvation Bio's filings show?

These are Nuvation Bio's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NUVB's financials

Didn't find what you were looking for?

Ask us
How much revenue did NUVB have in 2025?

Nuvation Bio had revenue of $63M and net income of -$205M in fiscal 2025, a net margin of -325.3%.

How much debt does NUVB have?

On December 31, 2025 Nuvation Bio had total assets of $595M, debt of $53M and shareholders' equity of $306M.

How much free cash flow does NUVB have?

In fiscal 2025 Nuvation Bio had cash from operations of -$173M and spent $8.0M on capital expenditure, leaving -$181M of free cash flow.

Where are the figures from?

From Nuvation Bio Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.